Beverage compositions comprising palatable calcium and magnesium sources

    公开(公告)号:US06616955B2

    公开(公告)日:2003-09-09

    申请号:US09754626

    申请日:2001-01-04

    Abstract: The present invention describes compositions comprising a calcium source and a magnesium source. The compositions are surprisingly palatable when delivered in a fruit juice beverage matrix at amounts which are nutritionally meaningful. In particular, the present invention relates to beverage compositions comprising: (a) a calcium source comprising a form selected from calcium carbonate, solubilized species thereof, and mixtures thereof; (b) at least about 20 milligrams of a magnesium source per reference serving of the composition; wherein the compositions are substantially free of milk base solids. In an another embodiment of the present invention, beverage compositions are described, comprising: (a) at least about 50 milligrams of a calcium source per reference serving of the composition; (b) at least about 20 milligrams of a magnesium source per reference serving of the composition, wherein the magnesium source comprises a form selected from magnesium carbonate, magnesium oxide, magnesium citrate, solubilized species thereof, and mixtures thereof; wherein the compositions are substantially free of milk base solids.

    METHOD FOR DETERMINING VASOREACTIVITY
    5.
    发明申请
    METHOD FOR DETERMINING VASOREACTIVITY 审中-公开
    测定血液活性的方法

    公开(公告)号:US20090029371A1

    公开(公告)日:2009-01-29

    申请号:US12096043

    申请日:2006-12-05

    Abstract: The present invention is generally directed to methods and materials for determining the genotype of a patient to predict the patient's vasoreactivity. More particularly, the present invention is directed to a method of determining the vasoreactivity of a subject, comprising: obtaining from a subject a sample comprising a nucleic acid sequence of the BMPR2 gene or amino acid sequence of the BMPR2 gene; determining the presence or absence of a non-synonymous mutation in the BMPR2 nucleic acid or amino acid sequence, and correlating the presence of a non-synonymous mutation with non-vasoreactivity or the absence of a non-synonymous mutation with vasoreactivity.

    Abstract translation: 本发明一般涉及用于确定患者的基因型以预测患者的血管反应性的方法和材料。 更具体地,本发明涉及确定受试者的血管反应性的方法,包括:从受试者获得包含BMPR2基因的核酸序列或BMPR2基因的氨基酸序列的样品; 确定BMPR2核酸或氨基酸序列中存在或不存在非同义突变,并将非同义突变的存在与非血管反应性或不同义突变与血管反应性相关联。

Patent Agency Ranking